Abstract:Heparin has been known to be a broad-spectrum inhibitor of viral infection for almost 70 years, and it has been used as a medication for almost 90 years due to its anticoagulant effect. This nontoxic biocompatible polymer efficiently binds to many types of viruses and prevents their attachment to cell membranes. However, the anticoagulant properties are limiting their use as an antiviral drug. Many heparin-like compounds have been developed throughout the years; however, the reversible nature of the virus inhibition mechanism has prevented their translation to the clinics. In vivo, such a mechanism requires the unrealistic maintenance of the concentration above the binding constant. Recently, we have shown that the addition of long hydrophobic linkers to heparin-like compounds renders the interaction irreversible while maintaining the low-toxicity and broad-spectrum activity. To date, such hydrophobic linkers have been used to create heparin-like gold nanoparticles and β-cyclodextrins. The former achieves a nanomolar inhibition concentration on a non-biodegradable scaffold. The latter, on a fully biodegradable scaffold, shows only a micromolar inhibition concentration. Here, we report that the addition of hydrophobic linkers to a new type of multifunctional scaffold (dendritic polyglycerol, dPG) creates biocompatible compounds endowed with nanomolar activity. Furthermore, we present an in-depth analysis of the molecular design rules needed to achieve irreversible virus inhibition. The most active compound (dPG-5) showed nanomolar activity against herpes simplex virus 2 (HSV-2) and respiratory syncytial virus (RSV), giving a proof-of-principle for broad-spectrum while keeping low-toxicity. In addition, we demonstrate that the virucidal activity leads to the release of viral DNA upon the interaction between the virus and our polyanionic dendritic polymers. We believe that this paper will be a stepping stone toward the design of a new class of irreversible nontoxic broad-spectrum antivirals.

Polyphosphate in Antiviral Protection: A Polyanionic Inorganic Polymer in the Fight Against Coronavirus SARS-CoV-2 Infection.

The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19)

An Unexpected Biomaterial Against SARS-CoV-2: Bio-polyphosphate Blocks Binding of the Viral Spike to the Cell Receptor.

The Inorganic Polymer, Polyphosphate, Blocks Binding Of Sars-Cov-2 Spike Protein To Ace2 Receptor At Physiological Concentrations

The Biomaterial Polyphosphate Blocks Stoichiometric Binding of the SARS-CoV-2 S-protein to the Cellular ACE2 Receptor.

Morphogenetic (Mucin Expression) As Well As Potential Anti-Corona Viral Activity Of The Marine Secondary Metabolite Polyphosphate On A549 Cells

Reversible rearrangement of the cellular cytoskeleton: A key to the broad-spectrum antiviral activity of novel amphiphilic polymers

Potent Antiviral and Antimicrobial Polymers as Safe and Effective Disinfectants for the Prevention of Infections

Inhibitory activities of alginate phosphate and sulfate derivatives against SARS-CoV-2 in vitro

Broad‐Spectrum Antiviral Peptides and Polymers

Polyanionic Amphiphilic Dendritic Polyglycerols as Broad-Spectrum Viral Inhibitors with a Virucidal Mechanism

Extracellular Polymeric Substances: Still Promising Antivirals

Future antiviral polymers by plasma processing

Supramolecular Architectures of Dendritic Polymers Provide Irreversible Inhibitor to Block Viral Infection

Star-polymers as potent broad-spectrum extracellular virucidal antivirals

Poly-l-lysine Glycoconjugates Inhibit DC-SIGN-mediated Attachment of Pandemic Viruses

Caged Dexamethasone/Quercetin Nanoparticles, Formed of the Morphogenetic Active Inorganic Polyphosphate, are Strong Inducers of MUC5AC

Caged Dexamethasone/Quercetin Nanoparticles, Formed of the Morphogenetic Active Inorganic Polyphosphate, are Strong Inducers of MUC5AC.

PDZ2-conjugated-PLGA nanoparticles are tiny heroes in the battle against SARS-CoV-2

Polydopamine-based nanomedicines for efficient antiviral and secondary injury protection therapy

Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication